Philippe Armand, MD, PhD

About Dr. Armand

Dr. Armand is a globally recognized leader in lymphoma research and treatment whose career has helped shape the modern landscape of immunotherapy and transplant strategies for patients with hematologic cancers. A physician-scientist with dual degrees (MD and PhD) from the University of California, San Francisco, Dr. Armand completed residency training in internal medicine at Brigham and Women’s Hospital and a fellowship in hematology/oncology through the Dana-Farber/Partners CancerCare program. He joined the Dana-Farber Cancer Institute (DFCI) in 2007, where he now serves as Chief of the Division of Lymphoma and holds the Harold and Virginia Lash Endowed Chair in Lymphoma Research.

At DFCI and Harvard Medical School, where he is Professor of Medicine, Dr. Armand is deeply engaged in advancing therapeutic strategies for both Hodgkin and non-Hodgkin lymphomas. He has particular expertise in CAR T-cell therapy, stem cell transplantation, and the development of clinical trials that integrate novel agents to improve patient outcomes. His work spans multiple programs including the Lymphoma Program, CNS Lymphoma Center, and Center for Chronic Lymphocytic Leukemia.

Board-certified in hematology, oncology, and internal medicine, Dr. Armand is known not only for his clinical acumen but also for his pioneering research that bridges laboratory insight and bedside innovation. His commitment to precision medicine and patient-centered care continues to drive progress in some of the most challenging areas of blood cancer treatment.